Encouraging Avastin results in glioblastoma multiforme

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Encouraging Avastin results in glioblastoma multiforme

DALLAS—Phase II data showed 6-month progression-free survival in 36% of relapsed glioblastoma patients given Avastin (bevacizumab) alone and 51% given Avastin plus irinotecan (Camptosar), compared with historical estimates of 15%. UCLA's Timothy Cloughesy, MD, reported the findings at the Society for Neuro-Oncology annual meeting.

Articles in this issue
Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets
Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Related Content
Treatment with IGV-001 demonstrated a 45% increase in overall survival compared with standard of care in patients with newly diagnosed glioblastoma.

Novel Cancer Vaccine Improves OS vs SOC in Newly Diagnosed GBM

Tim Cortese
December 3rd 2025
Article

Treatment with IGV-001 demonstrated a 45% increase in overall survival compared with standard of care in patients with newly diagnosed glioblastoma.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

One patient with newly diagnosed glioblastoma multiforme reached 3 years of survival following treatment with temferon in a phase 1/2a trial.

Temferon Yields Preliminary Survival in Newly Diagnosed Glioblastoma Trial

Russ Conroy
November 25th 2025
Article

One patient with newly diagnosed glioblastoma multiforme reached 3 years of survival following treatment with temferon in a phase 1/2a trial.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma

Tim Cortese
November 7th 2025
Article

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma

Roman Fabbricatore
October 30th 2025
Article

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.